CVS Ventures

CVS Health Ventures Research Overview CVS Health Ventures is the dedicated corporate venture capital (CVC) arm of CVS Health, one of the largest integrated healthcare companies in the United States. Founded in 2021, the fund launched with $100 million in committed capital and has since become one of the most active healthcare-focused CVCs in the country. CVS Health Ventures has made 43+ investments across digital health, value-based care, and healthcare technology, with 70%+ of portfolio companies maintaining active business relationships with CVS Health. Investment Thesis CVS Health Ventures invests in companies that advance healthcare innovation aligned with CVS Health's enterprise mission: making healthcare simpler, more accessible, and affordable. The fund operates across four strategic pillars: Empower Tech-Enabled Workflows — Solutions enabling healthcare workers through data, automation, and AI-driven insights Disruptive Technology — Technologies reshaping how care is delivered, financed, and experienced Simplifying Healthcare Complexity — Improving access, streamlining delivery, and reforming payment models Consumer-Centric Health — Personalized, seamless healthcare experiences powered by data The fund's unique strategic advantage lies in CVS Health's national omnichannel footprint — over 9,000 retail pharmacies, MinuteClinics, specialty pharmacies, Aetna insurance, and Oak Street Health primary care — which gives portfolio companies a direct route to scale and distribution. Stage Focus CVS Health Ventures is stage-agnostic by design. Vijay Patel has stated publicly that whether a company is pre-seed, seed, or pre-IPO, if CVS Health wants a strategic relationship, there is a pathway. In practice, the fund most frequently invests at: Pre-Seed/Seed : Smaller strategic checks ($1M–$5M) for early-stage healthcare innovators Series A / Series B : Core investment activity ($5M–$20M as a check, though rounds are larger) Series C and beyond : Follow-on and growth equity, with capacity for checks up to $100M Check Size Typical check size ranges from $1M to $20M for standard investments. CVS Health Ventures also operates a growth equity vehicle capable of writing $100M+ checks for later-stage portfolio companies or new large-scale opportunities. Given CVS Health's balance sheet, the fund has considerable flexibility. Lead Tendency CVS Health Ventures both leads and participates in rounds. They led Knownwell's $25M Series B (October 2025), AmplifAI's $33.7M Series B (September 2025), Cortica's $40M Series D extension (2023), and participated in rounds led by others such as Main Street Health ($315M) and Strive Health ($166M Series C). Recent Activity CVS Health Ventures has been highly active across 2024–2026: May 2026 : Strategic investment in Fathom, a leader in autonomous medical coding achieving 90%+ automation rates February 2026 : Participation in Big Health's $23.7M round led by .406 Ventures/AlleyCorp for FDA-cleared digital therapeutics (SleepioRx, DaylightRx) October 2025 : Led Knownwell's oversubscribed $25M round to scale obesity medicine and GLP-1 care model nationwide September 2025 : Led AmplifAI's $33.7M Series B for AI-powered contact center performance September 2025 : Portfolio exit — Thirty Madison acquired by Remedy Meds for $500M 2025 : Thyme Care achieved unicorn status (value-based oncology care) Portfolio Highlights The fund has 40+ portfolio companies spanning the full healthcare value chain. Notable companies include: Maven Clinic (NYC) — Women and family healthcare platform [Unicorn] Main Street Health (Nashville) — Rural value-based care provider [Unicorn] Thyme Care (Nashville) — Oncology value-based care [Unicorn, 2025] Abridge (Pittsburgh) — Generative AI clinical documentation Strive Health (Denver) — Value-based kidney disease care ($166M Series C) Oshi Health (NYC) — Virtual GI care ($30M Series B) Thirty Madison — Specialized health brands [Acquired by Remedy Meds, Sep 2025, $500M] Monogram Health — In-home care for complex chronic patients Cortica (San Diego) — Doctor-led autism care ($40M Series D) Synapticure — Neurodegenerative disease care platform WellBe Senior Medical — Senior home-based medical care Wayspring — Substance use disorder home care Workit — SUD recovery support Array Behavioral Health — Behavioral care across settings AbsoluteCare — Value-based primary care for Medicaid members Team The fund is led by Vijay Patel, co-founder and Managing Partner, who previously worked at H.I.G. Growth Partners and Bain Capital before joining CVS Health in 2015 to build out digital innovation and ventures. He holds a B.S. from the University of Pennsylvania (Jerome Fisher M&T Program) and an MBA from MIT Sloan. The investment team includes: Justin Brock — Partner Alex James — Partner Andrea Messina — Partner (Executive Director) Carter Prince — Partner Alyssa Reisner — Partner Payal Parikh — Principal Vinay Raj — Principal The team also includes senior associates, associates, and analysts across investment and market development functions. Decision Process As a corporate VC, investment decisions go through an investment committee process. The team sources and evaluates opportunities, and commitments are approved at the committee level within CVS Health's enterprise governance structure. Given corporate reporting requirements, decisions may take 4–8 weeks. Geographic Focus Primarily US-focused. The entire current portfolio is US-based, with geographic concentration in NYC, Boston, Nashville, Chicago, San Francisco/Bay Area, and San Diego/Los Angeles. Founder Preferences CVS Health Ventures tends to back experienced healthcare operators and clinician-founded companies addressing systemic inefficiencies in care delivery, value-based models, and whole-person health. They strongly prefer companies that can leverage CVS Health's distribution channels — pharmacies, MinuteClinics, Aetna insurance, and Oak Street Health. Companies that can become a clinical or distribution partner with CVS Health are most attractive. Anti-Thesis Areas CVS Health Ventures typically avoids: healthcare companies not aligned with US market, biotech/pharma drug development, medical devices without digital health component, and industries unrelated to healthcare.